IO-160
/ IO Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 13, 2023
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
(clinicaltrials.gov)
- P1 | N=10 | Completed | Sponsor: Inge Marie Svane | Unknown status ➔ Completed
Trial completion • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytosis • CALR
1 to 1
Of
1
Go to page
1